JLE

Epileptic Disorders

MENU

Antiepileptic drug trials: the view from the clinic Volume 14, issue 2, June 2012

Anderson M, Choonara I. A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period. Arch Dis Child 2010 ; 95 : 731-738.

Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000 ; 41 : 1597-1607.

Baulac M, Leon T, O’Brien TJ, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res 2010 ; 91 : 10-19.

Ben-Menachem E, Sander JW, Privitera M, Gilliam F. Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy Behav 2010 ; 18 : 24-30.

Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010 ; 51 : 7-26.

Brodie MA, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Research 1997; 26: 423-32.

Chadwick D, Shukralla A, Marson T. Comparing drug treatments in epilepsy. Ther Adv Neurol Disord 2009 ; 2 : 181-187.

Cowling BJ, Shaw JE, Hutton JL, Marson A.G. New statistical method for analyzing time to first seizure: example using data comparing carbamazepine and valproate monotherapy. Epilepsia 2007 ; 48 : 1173-1178.

Faught E, Ayala R, Montouris GG, Leppik IE, Zonisamide 922 Study Group Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001 ; 57 : 1774-1779.

French J.A. Proof of efficacy trials: endpoints. Epilepsy Research 2001 ; 45 : 53-56.

French JA, Faught E. Rational polytherapy. Epilepsia 2009 ; 50 : 63-68.

Garofalo E. Obtaining pediatric indications for new anti-epileptic drugs: how and when. Epilepsy Res 2006 ; 68 : 38-42.

Gilliam F. What we don’t learn from clinical trials in epilepsy. Epilepsia 2003 ; 44 : 51-54.

Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004 ; 62 : 23-27.

Gilliam FG, Barry JJ, Herman BP, Meador KJ, Vahle V, Kanner A.M. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006 ; 5 : 399-405.

Glauser T, Ben-Menachem E, Bourgeois B, et al. International League Against Epilepsy treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006 ; 47 : 1094-1120.

Glauser T, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010 ; 362 : 790-799.

Hopkins AC, Davies P, Dobson C. Mathematical models of patterns of seizures. Their use in the evaluation of drugs. Arch Neurol 1985 ; 42 : 463-467.

Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003; 60 (Suppl. 4): S2-S12.

Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011 ; 52 : 657-678.

Luszczki JJ, Filip D, Czuczwar S.J. Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Res 2010 ; 91 : 166-175.

Marson AG, Williamson P. Interpreting regulatory trials in epilepsy. Current Opinion in Neurology 2009 ; 22 : 167-173.

Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007 ; 369 : 1000-1015.

Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007 ; 369 : 1016-1026.

Meador KJ, Pennell PB, Harden CL, et al. Pregnancy registries in epilepsy. A consensus statement on health outcomes. Neurology 2008 ; 71 : 1109-1117.

Park SP, Kwon S.H. Cognitive effects of antiepileptic drugs. J Clin Neurol 2008 ; 4 : 99-106.

Pellock JM, Faught E, Leppik IO, Shinnar S, Zupanc ML. Felbamate: consensus of current experience. Epilepsy Research 2006; 71: 81-101.

Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs 2008 ; 22 : 917-938.

Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999 ; 33 : 247-262.

Perucca P, Carter J, Vahle V, Gilliam F.G. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009 ; 72 : 1223-1229.

Physician's Desk Reference. Keppra XR labeling recommendations; Lamictal labeling recommendations, PDR Consortium, 2011a, 2011b.

Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003 ; 107 : 165-175.

Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 2010 ; 51 : 1970-1975.

Rheims S, Percucca E, Cucherat M, Ryvlin P. Factors determing response to antiepileptic drugs in randomized controlled trials. A systematic review and metanalysis. Epilepsia 2011 ; 52 : 219-233.

Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy. A randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64:1868-73.

Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurology 2011; 10: 961-8.

Sake JK, Hebert D, Isojarvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010 ; 24 : 1055-1068.

Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg H.J. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982 ; 32 : 157-163.

Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006 ; 166 : 1092-1097.

Talati R, Scholle JM, Phung OJ, et al. Effectiveness and safety of antiepileptic medications in patients with epilepsy. Comparative Effectiveness Review No. 40. AHRQ Publication No. 11, 2011; (12)-EHC082-EF. Rockville (MD): Agency for Healthcare Research and Quality. www.effectivehealthcare.ahrq.gov/reports/final.cfm (accessed Jan 1, 2012).

Weijenberg A, Offringa M, Brouwer OF, Callenbach P.M. RCTs with new antiepileptic drugs in children: a systematic review of monotherapy studies and their methodology. Epilepsy Res 2010 ; 91 : 1-9.

World Health Organization. WHO defined daily doses of antiepileptic drugs. 2010. Retrieved 10 October 2011, from www.WHOCC.no/atc_ddd_index/?code=NO3A.